91. Budd-Chiari syndrome Clinical trials / Disease details
Clinical trials : 4 / Drugs : 5 - (DrugBank : 4) / Drug target genes : 4 - Drug target pathways : 14
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2100046725 | 2022-01-01 | 2021-05-27 | The efficacy and safety of Warfarin and Rivaroxaban to prevent re-occlusion for Budd-Chiari syndrome with membranous obstruction after percutanouse balloon angioplasty | To compare the efficacy and safety of Warfarin and Rivaroxaban to prevent re-occlusion for Budd-Chiari syndrome with membranous obstruction after percutanouse balloon angioplasty | Budd-Chiari syndrome | Warfarin group:oral take Warfarin;Rivaroxaban group:oral take rivaroxaban; | The First Affiliated Hospital of Zhengzhou University | NULL | Recruiting | 18 | 75 | Both | Warfarin group:40;Rivaroxaban group:40; | N/A | China |
| 2 | EUCTR2014-005162-29-NL (EUCTR) | 09/04/2020 | 13/06/2019 | Treatment of thrombosis in the abdominal veins | Treatment of portal, mesenteric, and splenic vein thrombosis with rivaroxaban. A pilot, prospective cohort study - RIVASVT100 | Splanchnic vein thrombosis (SVT) is an unusual site manifestation of venous thromboembolism (VTE). It includes the Budd-Chiari syndrome (BCS), portal vein thrombosis (PVT), mesenteric vein thrombosis (MVT) and splenic vein thrombosis (spVT). PVT is the most frequent manifestation of SVT, followed by MVT. ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] | Trade Name: rivaroxaban 20 mg Product Name: rivaroxaban | University of Insubria | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 100 | Phase 4 | France;Canada;Germany;Netherlands;Italy |